{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:43:07Z","timestamp":1762602187649,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.msard.2024.105940","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T13:36:29Z","timestamp":1728653789000},"page":"105940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The correlation between rituximab dose reduction and acute relapses of neuromyelitis optica spectrum disorder, lessons from COVID-19 epidemic"],"prefix":"10.1016","volume":"92","author":[{"given":"Fereshteh","family":"Ashtari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-1231","authenticated-orcid":false,"given":"Roshanak","family":"Mehdipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshia","family":"Ghalamkari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2024.105940_bib0001","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40249-020-00646-x","article-title":"Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review","volume":"9","author":"Adhikari","year":"2020","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.msard.2024.105940_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104852","article-title":"Epidemiologic and clinical characteristics of neuromyelitis optica spectrum disorder patients, A seven years follow-up study from Iran","volume":"77","author":"Ashtari","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105940_bib0003","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.msard.2019.06.013","article-title":"Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city","volume":"34","author":"Ashtari","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2024.105940_bib0004","doi-asserted-by":"crossref","first-page":"117","DOI":"10.32598\/CJNS.8.29.8","article-title":"The Impact of COVID-19 pandemic on neuromyelitis optica disorder patients, after one year","volume":"8","author":"Ashtari","year":"2022","journal-title":"Casp. J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2024.105940_bib0005","doi-asserted-by":"crossref","first-page":"e761","DOI":"10.1212\/NXI.0000000000000761","article-title":"Bar-Or A. COVID-19 and MS disease-modifying therapies","volume":"7","author":"Berger","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2024.105940_bib0006","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ibd\/izaa278","article-title":"Immunosuppressive therapy and risk of COVID-19 infection in patients with inflammatory bowel diseases","volume":"27","author":"Burke","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.msard.2024.105940_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117147","article-title":"COVID-19 in multiple sclerosis patients and risk factors for severe infection","volume":"418","author":"Chaudhry","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2024.105940_bib0008","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.105940_bib0009","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/1756285616632653","article-title":"An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica","volume":"9","author":"Collongues","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"10.1016\/j.msard.2024.105940_bib0010","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105940_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","author":"Cree","year":"2019","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105940_bib0012","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed."},{"issue":"3","key":"10.1016\/j.msard.2024.105940_bib0013","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejr.2021.05.001","article-title":"Six-month assessment of low dose rituximab in the treatment of rheumatoid arthritis during coronavirus disease 2019 (COVID-19) pandemic","volume":"43","author":"Durmaz","year":"2021","journal-title":"Egypt. Rheumatol."},{"key":"10.1016\/j.msard.2024.105940_bib0014","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105940_bib0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12883-021-02218-4","article-title":"Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD","volume":"21","author":"Esmaeili","year":"2021","journal-title":"BMC Neurol."},{"issue":"8","key":"10.1016\/j.msard.2024.105940_bib0016","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.nrl.2014.09.001","article-title":"Clinical evaluation of rituximab treatment for neuromyelitis optica","volume":"30","author":"Fern\u00e1ndez-Meg\u00eda","year":"2015","journal-title":"Neurologia"},{"key":"10.1016\/j.msard.2024.105940_bib0017","unstructured":"Filippi M.H.S., Oreja-Guevara C., Tanasescu R., Wiendl H., Immunotherapy for patients with neuroimmunological disorders during the COVID-19 pandemic. 2020 [Available from: https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/immunotherapy-for-patients-with-neuroimmunological-disorders-during-the-covid-19-pandemic."},{"issue":"10","key":"10.1016\/j.msard.2024.105940_bib0018","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105940_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102725","article-title":"COVID-19 in ocrelizumab-treated people with multiple sclerosis","volume":"49","author":"Hughes","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9950","key":"10.1016\/j.msard.2024.105940_bib0020","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.msard.2024.105940_bib0021","doi-asserted-by":"crossref","first-page":"e82325","DOI":"10.1371\/journal.pone.0082325","article-title":"Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.msard.2024.105940_bib0022","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3988\/jcn.2011.7.3.115","article-title":"New insights into neuromyelitis optica","volume":"7","author":"Kim","year":"2011","journal-title":"J. Clin. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105940_bib0023","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"Kumpfel","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105940_bib0024","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/ITT.S255722","article-title":"B-cell targeted treatments for neuromyelitis optica spectrum disorder: a focus on CD19 and CD20","volume":"10","author":"Levy","year":"2021","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.msard.2024.105940_bib0025","article-title":"New therapies for neuromyelitis optica spectrum disorder","author":"Levy","year":"2020","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.msard.2024.105940_bib0026","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with Coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2024.105940_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102185","article-title":"Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain","volume":"42","author":"Montero-Escribano","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2024.105940_bib0028","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000835","article-title":"COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2024.105940_bib0029","doi-asserted-by":"crossref","first-page":"732","DOI":"10.4103\/aian.AIAN_167_21","article-title":"Efficacy and safety of rituximab in central nervous system demyelinating disorders","volume":"24","author":"Patil","year":"2021","journal-title":"Ann. Indian Acad. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2024.105940_bib0030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/NRL.0000000000000371","article-title":"Recurrence of COVID-19 in a patient with NMO spectrum disorder while treating with rituximab: a case report and review of the literature","volume":"26","author":"Paybast","year":"2021","journal-title":"Neurologist"},{"issue":"15","key":"10.1016\/j.msard.2024.105940_bib0031","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105940_bib0032","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.msard.2024.105940_bib0033","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.105940_bib0034","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105940_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105940_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102869","article-title":"Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature","volume":"50","author":"Velasco","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105940_bib0037","unstructured":"WHO. Novel Coronavirus\u2013China. 2020. [Available from: https:\/\/www.who.int\/csr\/don\/12january-2020-novel-coronavirus-china\/en\/."},{"issue":"2","key":"10.1016\/j.msard.2024.105940_bib0038","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824005169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824005169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:41:16Z","timestamp":1762602076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824005169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"alternative-id":["S2211034824005169"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105940","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The correlation between rituximab dose reduction and acute relapses of neuromyelitis optica spectrum disorder, lessons from COVID-19 epidemic","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105940"}}